[1]
|
聂远航. 真实世界奥马珠单抗治疗中重度过敏性哮喘的临床观察[D]: [硕士学位论文]. 汕头: 汕头大学, 2021.
|
[2]
|
国家呼吸系统疾病临床医学研究中心, 中华医学会儿科学分会呼吸学组哮喘协作组, 中国医药教育协会儿科专业委员会, 等. 奥马珠单抗在儿童过敏性哮喘临床应用专家共识[J]. 中华实用儿科临床杂志, 2021, 36(12): 881-890.
https://doi.org/10.3760/cma.j.cn101070-20210531-00621
|
[3]
|
中华医学会变态反应分会呼吸过敏学组(筹), 中华医学会呼吸病学分会哮喘学组. 中国过敏性哮喘诊治指南(第一版, 2019年) [J]. 中华内科杂志, 2019, 58(9): 636-655.
|
[4]
|
Global Initiative for Asthma (2020) Global Strategy for Asthma Management and Prevention. http://ginasthma.org
|
[5]
|
中华医学会呼吸病学分会哮喘学组. 支气管哮喘防治指南(2020年版) [J]. 中华结核和呼吸杂志, 2020, 43(12): 1023-1048. https://doi.org/10.3760/cma.j.cn112147-20200618-00721
|
[6]
|
邢斌. 重症哮喘诊断与处理中国专家共识[J]. 中华结核和呼吸杂志, 2017, 40(11): 813-829.
|
[7]
|
Oliveria, J.P., Agayby, R. and Ganweau, G.M. (2021) Regulatory and IgE+ B Cells in Allergic Asthma. In: Mion, F. and Tonon, S., Eds., Regula-tory B Cells, Humana, New York, 375-418. https://doi.org/10.1007/978-1-0716-1237-8_21
|
[8]
|
Tan, R., Liew, M.F., Lim, H.F., Leung, B.P. and Wong, W.S.F. (2020) Promises and Challenges of Biologics for Severe Asthma. Bio-chemical Pharmacology, 179, Article ID: 114012. https://doi.org/10.1016/j.bcp.2020.114012
|
[9]
|
Tenero, L., Rossignoli, S. and Piacentini, G. (2020) Severe Asthma: When to Resort to Biological Agents. Pediatric Allergy and Immunology, 31, 37-39. https://doi.org/10.1111/pai.13162
|
[10]
|
Loureiro, C.C., Amaral, L., Ferreira, J.A., et al. (2018) Omalizumab for Severe Asthma: Beyond Allergic Asthma. BioMed Research International, 2018, Article ID: 3254094. https://doi.org/10.1155/2018/3254094
|
[11]
|
Zhao, Z.T., Ji, C.M., Yu, W.J., et al. (2016) Omalizumab for the Treatment of Chronic Spontaneous Urticaria: A Meta-Analysis of Randomized Clinical Trials. Journal of Allergy and Clinical Immunology, 137, 1742-1750.E4.
https://doi.org/10.1016/j.jaci.2015.12.1342
|
[12]
|
Licari, A., Marseglia, G., Castagnoli, R., Marseglia, A. and Ciprandi, G. (2015) The Discovery and Development of Omalizumab for the Treatment of Asthma. Expert Opinion on Drug Discovery, 10, 1033-1042.
https://doi.org/10.1517/17460441.2015.1048220
|
[13]
|
Navines-Fetter, A., Serrano-Candelas, E., Molina-Molina, G.J. and Martín, M. (2016) IgE-Related Chronic Diseases and Anti-IgE-Based Treatments. Journal of Immunology Re-search, 2016, Article ID: 8163803.
https://doi.org/10.1155/2016/8163803
|
[14]
|
Lovinsky-Desir, S. (2020) The Use of Biologic Therapies for the Management of Pediatric Asthma. Pediatric Pulmonology, 55, 803-808. https://doi.org/10.1002/ppul.24613
|
[15]
|
Balbino, B., Herviou, P., Godon, O., et al. (2020) The Anti-IgE mAb Omalizumab Induces Adverse Reactions by Engaging Fcγ Receptors. Journal of Clinical Investigation, 130, 1330-1335. https://doi.org/10.1172/JCI129697
|
[16]
|
中华医学会呼吸病学分会哮喘学组. 奥马珠单抗治疗过敏性哮喘的中国专家共识(2021版)[J]. 中华结核和呼吸杂志, 2022, 45(4): 341-354. https://doi.org/10.3760/cma.j.cn112147-20220115-00051
|
[17]
|
Asano, K., Sumi, K., Yoshisue, H., et al. (2020) Real-Life Safety and Efficacy of Omalizumab in Japanese Patients with Severe Allergic Asthma Who Were Subjected to Dosing Table Revision or Expansion: A Post-Marketing Surveillance. Pulmonary Pharmacology & Therapeutics, 64, Article ID: 101950.
https://doi.org/10.1016/j.pupt.2020.101950
|
[18]
|
Humbert, M., Taille, C., Mala, L., et al. (2018) Omalizumab Effec-tiveness in Patients with Severeallergic Asthma according to Blood Eosinophil Count: The STELLAIR Study. European Respiratory Journal, 51, Article ID: 1702523.
https://doi.org/10.1183/13993003.02523-2017
|
[19]
|
Mansur, A.H., Srivastava, S., Mitchell, V., Sullivan, J. and Kasujee, I. (2017) Longterm Clinical Outcomes of Omalizumab Therapy in Severe Allergic Asthma: Study of Efficacy and Safety. Respiratory Medicine, 124, 36-43.
https://doi.org/10.1016/j.rmed.2017.01.008
|
[20]
|
张晶鑫, 刘传和. 抗IgE抗体在儿童支气管哮喘中的应用及研究进展[J]. 临床药物治疗杂志, 2018, 16(6): 16-20.
|
[21]
|
马婷婷, 王向东, 陈艳蕾, 等. 奥马珠单抗治疗花粉症伴中重度哮喘患者的临床疗效及安全性研究[J]. 中国耳鼻咽喉头颈外科, 2018, 25(12): 675-678.
|
[22]
|
Bhutani, M., Yang, W.H., Hebert, J., de Takacsy, F. and Stril, J.L. (2017) The Real World Effect of Omalizu-Mab Add on Therapy for Patients with Moderate to Severe Allergic Asthma: The ASTERIX Observational Study. PLOS ONE, 12, e183869. https://doi.org/10.1371/journal.pone.0183869
|
[23]
|
Jahnz-Rózyk, K., Lis, J., Warchoł, M. and Kucharczyk, A. (2018) Clinical and Economic Impact of a One-Year Treatment with Omalizumab in Patients with Severe Allergic Asth-ma within a Drug Programme in Poland. BMC Pulmonary Medicine, 18, Article No. 48. https://doi.org/10.1186/s12890-018-0610-z
|
[24]
|
Busse, W.W., Humbert, M., Haselkom, T., et a1. (2020) Effect of Omalizumab on Lung Function and Eosinophil Levels in Adolescents with Moderateto-Severe Aller-Gicasthma. Annals of Allergy, Asthma & Immunology, 124, 190-196. https://doi.org/10.1016/j.anai.2019.11.016
|
[25]
|
Licari, A., Castagnoli, R., Denicolo, C., et al. (2017) Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience. Current Respiratory Medicine Reviews, 13, 36-42.
https://doi.org/10.2174/1573398X13666170426094536
|
[26]
|
Solidoro, P., Patrucco, F., de Blasio, F., et al. (2019) Predictors of Reversible Airway Obstruction with Omalizumab in Severe Asthma: A Real-Life Study. Therapeutic Ad-vances in Respiratory Disease, 13.
https://doi.org/10.1177/1753466619841274
|
[27]
|
Domingo, C., Pomares, X., Navarro, A., et al. (2018) A Step-Down Protocol for Omalizumab Treatment in Oralcorticosteroid-Dependent Allergic Asthma Patients. British Journal of Clinical Pharmacology, 84, 339-348.
https://doi.org/10.1111/bcp.13453
|
[28]
|
Chipps, B.E., Lanier, B., Milgrom, H., et al. (2017) Omalizumab in Children with Uncontrolled Allergic Asthma: Review of Clinical Trial and Real-World Experience. Journal of Allergy and Clinical Immunology, 139, 1431-1444.
https://doi.org/10.1016/j.jaci.2017.03.002
|
[29]
|
林江涛. 抗IgE治疗变应性哮喘的长期有效性和安全性[J]. 中华结核和呼吸杂志, 2016, 39(9): 733-736.
|
[30]
|
沙莉, 刘传合. 生物制剂治疗支气管哮喘的研究进展[J]. 山东大学耳鼻喉眼学报, 2019, 33(1): 53-58.
|
[31]
|
徐艳华, 王菁兰, 王怡玮, 等. 33例141次奥马珠单抗治疗后不良反应回顾性研究[J]. 中华临床免疫和变态反应杂志, 2019, 13(6): 516-519.
|
[32]
|
Humbert, M., Beasley, R., Ayres, J., et al. (2005) Benefits of Omalizumab as Add-on Therapy in Patients with Severe Persistent Asthma Who Are Inadequately Controlled Despite Best Available Therapy (GINA 2002 Step 4 Treatment): INNOVATE. Allergy, 60, 309-316.
|
[33]
|
戴然然, 周新. 奥马珠单抗治疗哮喘的临床应用进展[J]. 国际呼吸杂志, 2016, 36(13): 998-1001.
https://doi.org/10.3760/cma.j.issn.1673-436X.2016.13.009
|
[34]
|
Bousquet, J., Rabe, K., Humbert, M., et al. (2007) Predicting and Evaluating Response to Omalizumab in Patients with Severe Allergic Asthma. Respiratory Medicine, 101, 1483-1492. https://doi.org/10.1016/j.rmed.2007.01.011
|
[35]
|
马晓伟. 奥马珠单抗联合布地奈德福莫特罗对IgE介导的哮喘患者临床疗效评价[D: [硕士学位论文]. 济南: 山东大学, 2021.
|
[36]
|
Stokes, J. (2017) Anti-IgE Treat-ment for Disorders Other than Asthma. Frontiers in Medicine, 4, Article 152.
https://doi.org/10.3389/fmed.2017.00152
|
[37]
|
Zierau, L., Waisted, E.S., Thomsen, S.F., et al. (2017) Response to Omalizumab in Patients with Severe Allergic Asthma: A Real-Life Study. Respiratory Medicine, 131, 109-113. https://doi.org/10.1016/j.rmed.2017.08.011
|
[38]
|
Casale, T.B., Chipps, B.E., Rosén, K., et al. (2018) Response to Omalizumab Using Patient Enrichment Criteria from Trials of Novel Biologics in Asthma. Allergy, 73, 490-497. https://doi.org/10.1111/all.13302
|
[39]
|
蔡慧, 墨玉清, 薛小敏, 等. 真实世界奥马珠单抗治疗中重度过敏性哮喘的疗效及安全性[J]. 中华临床免疫和变态反应杂志, 2019, 13(3): 199-204.
|
[40]
|
Brooks, E.A., Massanari, M., Hanania, N.A. and Weiner, D.J. (2019) Cost-Effectiveness of Feactional Exhaled Nitri coxide (FeNO) Measurement in Predicting Response to Amalizumab in Asthma. ClinicoEconomics and Outcomes Research, 11, 301-307. https://doi.org/10.2147/CEOR.S177207
|
[41]
|
毛雅, 丁美, 梁慧玲, 等. 奥马珠单抗在过敏性哮喘中对哮喘和致敏的作用[J]. 医药导报, 2021, 40(12): 1684-1690.
|